MedTrace Logo

Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

NCT06277921 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2025-07-02

No results posted yet for this study

Summary

Esophageal and esophagogastric junction cancer is still one of the main health care issue and esophagectomy with lymph node dissection is the only chance to be cure.

However, esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24% and a mortality rate of 2% to 5.6%, respectively There is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.

Conditions

  • Esophageal Cancer
  • Oesophageal Cancer
  • Siewert Type I Adenocarcinoma of Esophagogastric Junction
  • Siewert Type III Adenocarcinoma of Esophagogastric Junction

Interventions

PROCEDURE

Elective Surgery for gastric cancer

Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach

Sponsors & Collaborators

  • National Medical Research Radiological Centre of the Ministry of Health of Russia

    collaborator OTHER

  • P. Herzen Moscow Oncology Research Institute

    lead OTHER_GOV

Principal Investigators

  • Andrey Ryabov, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Vladimir Khomyakov, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Nuriddin Abdulkhakimov, MD, PhD · P.Herzen Moscow Oncological Research Institute

  • Pavel Smirnov · P.Herzen Moscow Oncological Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-18
Primary Completion
2024-09-18
Completion
2025-01-20

Countries

  • Belarus
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277921 on ClinicalTrials.gov